Partecipa allo studio EROICASS - ExtracoRporeal bloOd PurifICation TherApies and Sequential Extracoporeal Support
Study design:
This is a national, non-profit, non-interventional, multicentre observational prospective cohort study.
Study duration: 12 months
Setting
All consecutive patients with septic shock at the participating centers will be prospectively enrolled. Patient enrolment will coincide with ICU admission. Patients will be monitored and data recorded until hospital discharge. This is an observational study: enrolled patients will not receive additional treatments other than those routinely administered in ICU. All clinical parameters, including those related to EBPT treatment, will be recorded in the web-based CRF.
Primary endpoint:
Primary endpoint is the absolute risk of undergoing EBPT during ICU stay, in critical ill adult patients with septic shock.
Secondary endpoints:
1. Risk ratio for mortality (28-day and 90-day) according to EBPT utilization.
2. Absolute risk of EBPT utilization for septic shock during ICU stay in critical ill patients stratified by presence/absence of AKI
3. Description of EBPT in terms of indication, modality and timing. EBPT description will be also reported stratifying population according to presence/absence of AKI.
4. Absolute risk of SETS and description of SETS in terms of indication, modality and timing.
5. Risk ratio for mortality (28-day and 90-day) according to SETS utilization.
6. Summary statistics for lactates, VIS, SOFA score and AKI staged (with KDIGO criteria) before and after EBPT and SETS, evaluating statistical changes.
7. Association between 90-day mortality and changes in blood lactate, VIS, SOFA score and AKI staged (with KDIGO criteria) in patients undergoing EBPT and undergoing SETS.
8. Association between 90-day mortality and fluid accumulation at EBPT initiation.
9. For patients undergoing EBPT/SETS, risk factors for 90-day mortality will be identify among demographic and clinical variables recorded at enrolment and at EBPT/SETS initiation.
10. For patients undergoing EBPT/SETS, impact of EBPT/SETS timing will be assess renal outcomes, mortality, ICU and hospital length of stay, 28-day free-EBPT (free-SETS days).
Number of patients : maximum of 38